Related references
Note: Only part of the references are listed.Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2009)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Molecular characterization of the pediatric preclinical testing panel
Geoffrey Neale et al.
CLINICAL CANCER RESEARCH (2008)
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
John M. Maris et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing of dasatinib by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Tomas Frgala et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis
Craig C. Whiteford et al.
CANCER RESEARCH (2007)
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
L Larizza et al.
LEUKEMIA & LYMPHOMA (2005)
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
S Batra et al.
CANCER RESEARCH (2004)
Molecular cytogenetic characterization of rhabdomyosarcoma cell lines
S Rodriguez-Perales et al.
CANCER GENETICS AND CYTOGENETICS (2004)
Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells
BK Law et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Developmental Therapeutics Program at the NCI: molecular target and drug discovery process
M Monga et al.
LEUKEMIA (2002)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
K Podsypanina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Short tandem repeat profiling provides an international reference standard for human cell lines
JR Masters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
JI Johnson et al.
BRITISH JOURNAL OF CANCER (2001)
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
N Keshelava et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Share Paper
